112 related articles for article (PubMed ID: 21215810)
1. NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
van der Straaten HM; Paquay MM; Tilanus MG; van Geloven N; Verdonck LF; Huisman C
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1231-6. PubMed ID: 21215810
[TBL] [Abstract][Full Text] [Related]
2. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
Jaskula E; Lange A; Kyrcz-Krzemien S; Markiewicz M; Dzierzak-Mietla M; Jedrzejczak WW; Czajka P; Mordak-Domagala M; Lange J; Gronkowska A; Nowak J; Warzocha K; Hellmann A; Kowalczyk J; Drabko K; Gozdzik J; Mizia S;
Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
[TBL] [Abstract][Full Text] [Related]
3. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation.
Granell M; Urbano-Ispizua A; Aróstegui JI; Fernández-Avilés F; Martínez C; Rovira M; Rius J; Plaza S; Gaya A; Navarro A; Talarn C; Carreras E; Monzó M; Montserrat E; Yagüe J
Haematologica; 2006 Oct; 91(10):1372-6. PubMed ID: 17018387
[TBL] [Abstract][Full Text] [Related]
4. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
5. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation.
Hildebrandt GC; Granell M; Urbano-Ispizua A; Wolff D; Hertenstein B; Greinix HT; Brenmoehl J; Schulz C; Dickinson AM; Hahn J; Rogler G; Andreesen R; Holler E
Biol Blood Marrow Transplant; 2008 Jan; 14(1):67-74. PubMed ID: 18158963
[TBL] [Abstract][Full Text] [Related]
6. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation.
Holler E; Rogler G; Brenmoehl J; Hahn J; Greinix H; Dickinson AM; Socie G; Wolff D; Finke J; Fischer G; Jackson G; Rocha V; Hilgendorf I; Eissner G; Marienhagen J; Andreesen R
Int J Immunogenet; 2008 Aug; 35(4-5):381-4. PubMed ID: 18976442
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children.
Gruhn B; Intek J; Pfaffendorf N; Zell R; Corbacioglu S; Zintl F; Beck JF; Debatin KM; Steinbach D
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1571-7. PubMed ID: 19896081
[TBL] [Abstract][Full Text] [Related]
9. Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation.
Wermke M; Maiwald S; Schmelz R; Thiede C; Schetelig J; Ehninger G; Bornhäuser M; Wassmuth R
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1718-27. PubMed ID: 20541026
[TBL] [Abstract][Full Text] [Related]
10. NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation.
van der Velden WJ; Blijlevens NM; Maas FM; Schaap NP; Jansen JH; van der Reijden BA; Feuth T; Dolstra H; Donnelly JP
Bone Marrow Transplant; 2009 Aug; 44(4):243-8. PubMed ID: 19219079
[TBL] [Abstract][Full Text] [Related]
11. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation.
Elmaagacli AH; Koldehoff M; Hindahl H; Steckel NK; Trenschel R; Peceny R; Ottinger H; Rath PM; Ross RS; Roggendorf M; Grosse-Wilde H; Beelen DW
Transplantation; 2006 Jan; 81(2):247-54. PubMed ID: 16436969
[TBL] [Abstract][Full Text] [Related]
12. Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation.
Madrigal A; Shaw BE
Blood Cells Mol Dis; 2008; 40(1):40-3. PubMed ID: 17964196
[TBL] [Abstract][Full Text] [Related]
13. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
14. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
Falda M; Busca A; Baldi I; Mordini N; Bruno B; Allione B; Rambaldi A; Morello E; Narni F; Santarone S; Locatelli F; Bacigalupo A;
Am J Hematol; 2007 Oct; 82(10):863-6. PubMed ID: 17616972
[TBL] [Abstract][Full Text] [Related]
15. No impact of NOD2/CARD15 on outcome after SCT.
Sairafi D; Uzunel M; Remberger M; Ringdén O; Mattsson J
Bone Marrow Transplant; 2008 Jun; 41(11):961-4. PubMed ID: 18317454
[TBL] [Abstract][Full Text] [Related]
16. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
18. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
20. Impact of NOD2/CARD15 haplotypes on the outcome after kidney transplantation.
Krüger B; Böger CA; Schröppel B; Obed A; Hoffmann U; Murphy BT; Fischereder M; Holler E; Banas B; Krämer BK
Transpl Int; 2007 Jul; 20(7):600-7. PubMed ID: 17498224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
